13 Aug 2024 • The U.S. FDA has approved an epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis, in both adult and pediatric patients who weigh at least 30kgs.

This approval provides the first epinephrine product for the treatment of anaphylaxis that is not administered by injection.

• The spray is a single-dose nasal application for one nostril; a second dose can be administered if symptoms persist or worsen.
• It comes with a warning that certain nasal conditions, such as nasal polyps or a history of nasal surgery, may affect absorption, and patients with these conditions should consult with a health care professional to consider use of an injectable epinephrine product.
• The most common side effects of neffy include throat irritation, intranasal paresthesia, headache, nasal discomfort, feeling jittery, tingling sensation, fatigue, tremor, rhinorrhea, nasal pruritus, sneezing, abdominal pain, gingival pain, oral hypoesthesia, nasal congestion, dizziness, nausea and vomiting.

Source: FDA | Read full story